Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes
Mellitus

J 2015

Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus

KATUCHOVA, Jana; Denisa HARVANOVA; Timea SPAKOVA; Rastislav KALANIN; Daniel FARKAS et. al.

Základní údaje

Originální název

Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus

Autoři

KATUCHOVA, Jana (703 Slovensko); Denisa HARVANOVA (703 Slovensko); Timea SPAKOVA (703 Slovensko); Rastislav KALANIN (703 Slovensko); Daniel FARKAS (703 Slovensko); Peter DURNY (703 Slovensko); Jan ROSOCHA (703 Slovensko); Jozef RADONAK (703 Slovensko); Daniel PETROVIC (705 Slovinsko); Dario SINISCALCO (380 Itálie); Meirigeng QI (840 Spojené státy); Miroslav NOVÁK (203 Česká republika, domácí) a Peter KRUŽLIAK (203 Česká republika, garant)

Vydání

Endocrine Pathology, Totowa, Humana Press INC, 2015, 1046-3976

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.817

Kód RIV

RIV/00216224:14110/15:00085444

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1007/s12022-015-9362-y

UT WoS

000354617600001

EID Scopus

2-s2.0-84939940977

Klíčová slova anglicky

Diabetes type 1; Mesenchymal stem cells; Insulin; Islet-producing cells

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 12. 2015 15:05, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Diabetes mellitus type 1 is a form of diabetes mellitus that results from the autoimmune destruction of insulin-producing beta cells in the pancreas. The current gold standard therapy for pancreas transplantation has limitations because of the long list of waiting patients and the limited supply of donor pancreas. Mesenchymal stem cells (MSCs), a relatively new potential therapy in various fields, have already made their mark in the young field of regenerative medicine. Recent studies have shown that the implantation of MSCs decreases glucose levels through paracrine influences rather than through direct transdifferentiation into insulin-producing cells. Therefore, these cells may use pro-angiogenic and immunomodulatory effects to control diabetes following the cotransplantation with pancreatic islets. In this review, we present and discuss new approaches of using MSCs in the treatment of diabetes mellitus type 1.

Citovat

KATUCHOVA, Jana; Denisa HARVANOVA; Timea SPAKOVA; Rastislav KALANIN; Daniel FARKAS; Peter DURNY; Jan ROSOCHA; Jozef RADONAK; Daniel PETROVIC; Dario SINISCALCO; Meirigeng QI; Miroslav NOVÁK a Peter KRUŽLIAK. Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus. Endocrine Pathology. Totowa: Humana Press INC, 2015, roč. 26, č. 2, s. 95-103. ISSN 1046-3976. Dostupné z: https://doi.org/10.1007/s12022-015-9362-y.

@article{1322325,
   author = {Katuchova, Jana and Harvanova, Denisa and Spakova, Timea and Kalanin, Rastislav and Farkas, Daniel and Durny, Peter and Rosocha, Jan and Radonak, Jozef and Petrovic, Daniel and Siniscalco, Dario and Qi, Meirigeng and Novák, Miroslav and Kružliak, Peter},
   article_location = {Totowa},
   article_number = {2},
   doi = {https://doi.org/10.1007/s12022-015-9362-y},
   keywords = {Diabetes type 1; Mesenchymal stem cells; Insulin; Islet-producing cells},
   language = {eng},
   issn = {1046-3976},
   journal = {Endocrine Pathology},
   title = {Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus},
   volume = {26},
   year = {2015}
}

TY  - JOUR
ID  - 1322325
AU  - Katuchova, Jana - Harvanova, Denisa - Spakova, Timea - Kalanin, Rastislav - Farkas, Daniel - Durny, Peter - Rosocha, Jan - Radonak, Jozef - Petrovic, Daniel - Siniscalco, Dario - Qi, Meirigeng - Novák, Miroslav - Kružliak, Peter
PY  - 2015
TI  - Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus
JF  - Endocrine Pathology
VL  - 26
IS  - 2
SP  - 95-103
EP  - 95-103
PB  - Humana Press INC
SN  - 10463976
KW  - Diabetes type 1
KW  - Mesenchymal stem cells
KW  - Insulin
KW  - Islet-producing cells
N2  - Diabetes mellitus type 1 is a form of diabetes mellitus that results from the autoimmune destruction of insulin-producing beta cells in the pancreas. The current gold standard therapy for pancreas transplantation has limitations because of the long list of waiting patients and the limited supply of donor pancreas. Mesenchymal stem cells (MSCs), a relatively new potential therapy in various fields, have already made their mark in the young field of regenerative medicine. Recent studies have shown that the implantation of MSCs decreases glucose levels through paracrine influences rather than through direct transdifferentiation into insulin-producing cells. Therefore, these cells may use pro-angiogenic and immunomodulatory effects to control diabetes following the cotransplantation with pancreatic islets. In this review, we present and discuss new approaches of using MSCs in the treatment of diabetes mellitus type 1.
ER  -

KATUCHOVA, Jana; Denisa HARVANOVA; Timea SPAKOVA; Rastislav KALANIN; Daniel FARKAS; Peter DURNY; Jan ROSOCHA; Jozef RADONAK; Daniel PETROVIC; Dario SINISCALCO; Meirigeng QI; Miroslav NOVÁK a Peter KRUŽLIAK. Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus. \textit{Endocrine Pathology}. Totowa: Humana Press INC, 2015, roč.~26, č.~2, s.~95-103. ISSN~1046-3976. Dostupné z: https://doi.org/10.1007/s12022-015-9362-y.

Přehled o publikaci